From: Phase II study of weekly paclitaxel and capecitabine in patients with metastatic or recurrent esophageal squamous cell carcinoma
Tumor Response
Prior regimen (N = 20)
IP
FP
DP
NP
Complete response
0
1
Partial response
4
2
Stable disease
Progressive disease
3
Total
7
6